Evidence map›Paper›PMID 40701148›Full record

ArticleCell reports2025

A STAT3/integrin axis accelerates pancreatic cancer initiation and progression.

Alejandro D Campos, Ryan M Shepard, Zachary Ortega, Ingrid Heumann, Anna E Wilke, Arin Nam, Carson Cable, Kourosh Kouhmareh, Richard Klemke, Nicole M Mattson and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Alejandro D CamposDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Ryan M ShepardDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Zachary OrtegaDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Ingrid HeumannDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Anna E WilkeDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Arin NamDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Carson CableDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Kourosh KouhmarehDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Richard KlemkeDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Nicole M MattsonDivision of Genomics and Precision Medicine, Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.
Trey IdekerDivision of Genomics and Precision Medicine, Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA; Departments of Bioengineering and Computer Science and Engineering, University of California San Diego, La Jolla, San Diego, CA, USA.
Camila De Arruda SaldanhaSchool of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.
Sven HeinzSchool of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.
Valerie WeaverDepartment of Surgery and Center for Bioengineering and Tissue Regeneration, University of California San Francisco, San Francisco, CA, USA.
Tami Von SchalschaDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Hiromi I WetterstenDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
Sara M WeisDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA.
David A ChereshDepartment of Pathology, Moores Cancer Center at the University of California San Diego, La Jolla, San Diego, CA, USA; Department of Pathology, Sanford Consortium for Regenerative Medicine at the University of California San Diego, La Jolla, San Diego, CA, USA. Electronic address: dcheresh@health.ucsd.edu.

Funding

The Cancer Cell Map Initiative v2.0U54CA274502 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Antoine Forget · 2022 to 2026
$14.2M
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2017 to 2021
$10.9M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Tissue mechanics reprograms the tissue to malignancy and metastasisR35CA242447 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VALERIE MARIE WEAVER · 2020 to 2026
$6.6M
Attacking stress tolerance in cancerR35CA220512 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERESH, DAVID A · 2018 to 2024
$6.5M
How transcription disrupts genome 3D organizationR01GM129523 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HEINZ, SVEN W · 2020 to 2023
$1.3M
αvβ3-induced epithelial cancer progression via macrophage recruitmentK01OD030513 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WETTERSTEN, HIROMI INOUE · 2021 to 2025
$647k
Targeting a Novel Pocket on ITGAVK00CA274649 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NICOLE MATTSON · 2023 to 2026
$368k
NCI NIH HHS K00 CA274649NCI NIH HHS R35 CA220512NCI NIH HHS R35 CA242447NCI NIH HHS T32 CA121938NCI NIH HHS U54 CA209891NCI NIH HHS U54 CA274502NIGMS NIH HHS R01 GM129523NIGMS NIH HHS T32 GM007752NIH HHS K01 OD030513
6 · The paper itself

Abstract

The signal transducer and activator of transcription 3 (STAT3) pathway drives pancreatic ductal adenocarcinoma (PDAC) progression by coordinating cellular responses to stress and inflammation. We perform ChIP-seq on hypoxia- or oncostatin-M-treated PDAC cells to identify sites at which phospho-STAT3 binds to regulate the expression of genes linked to poor survival. A top hit among these is ITGB3, which we show promotes PDAC initiation and progression. Single-cell transcriptomics reveal that ITGB3 expression is enriched in PDAC cells experiencing oxidative stress due to chemotherapy. Moreover, high ITGB3 expression positively correlates with STAT3 signaling, hypoxia, and the basal subtype. Mechanistically, chromatin accessibility at ITGB3 enhancers controls STAT3's ability to induce ITGB3 expression, illuminating a plastic regulatory mechanism modulating STAT3 activity. Leveraging this insight, we identify additional STAT3 target genes regulated similarly to ITGB3 to establish an 18-gene signature involved in adaptive responses and able to stratify survival outcomes. Collectively, these findings highlight a novel opportunity to stratify PDAC subpopulations for STAT3-targeted therapies.

Indexed as

Carcinoma, Pancreatic DuctalIntegrin beta3Pancreatic NeoplasmsSTAT3 Transcription FactorAnimalsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMiceSignal TransductionIntegrin beta3ITGB3 protein, humanSTAT3 protein, humanSTAT3 Transcription Factorcellular stressCP: Cancercytokineenhancergene signaturehypoxiainflammationintegrinpancreatic cancerSTAT3tumor initiation

Identifiers

PMID40701148
PMCPMC12445075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.